Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesize that, among non-hypertensive overweight and obese individuals, treatment of vitamin D deficiency and lowering uric acid concentrations (by either xanthine oxidase inhibition or increased renal excretion) will attenuate renin angiotensin system (RAS) activation, improve endothelial function, and lower blood pressure.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Brigham and Women's Hospital
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Allopurinol; Ergocalciferols; Probenecid; Uric Acid; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• 25(OH)D < 20 ng/mL OR Uric acid ≥ 5 mg/dL

• Age ≥ 18, ≤ 75 years

• Body Mass Index (BMI) ≥ 25 kg/m^2

Exclusion Criteria:

• Hypertension, or on BP-lowering medicine

• Diabetes

• Coronary Heart Disease

• estimated glomerular filtration rate (EGFR) <60 mL/min

• Kidney stones

• Active cancer (except non-melanoma skin cancer)

• Pregnant

• Taking vitamin D supplements and unwilling to stop

• Osteoporosis

• Hypo- or hypercalcemia

• Hypo- or hyperphosphatemia

• Known allergy to angiotensin-converting enzyme (ACE)-inhibitors

• Taking medication for hyperuricemia

• Gout, anemia, cirrhosis, active/chronic hepatitis, abnormal aspartate aminotransferase (AST), alanine aminotransferase (ALT) or total bilirubin levels, or anemia

• Known allergy to either allopurinol or probenecid

• Current use of didanosine, azothioprine, methotrexate, ketoprofen, ketorolac, mycophenolate, or ACE-inhibitors